GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.76 USD | +0.91% |
|
-1.92% | -17.59% |
| Apr. 19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
| Apr. 19 | BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89 | MT |
Presenter SpeechJacquie Ross (Executives)Good morning or good afternoon to you all, and thank ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
66.76
USD
Average target price
85.25
USD
Spread / Average Target
+27.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.59% | 83.25B | |
| +24.60% | 654B | |
| +24.08% | 552B | |
| -5.63% | 356B | |
| +15.37% | 319B | |
| +7.38% | 295B | |
| +3.26% | 211B | |
| +0.78% | 206B | |
| -9.69% | 147B | |
| -6.63% | 144B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Transcript : Gilead Sciences, Inc. - Special Call
